Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial …
H Minatogawa, N Izawa, K Shimomura… - British Journal of …, 2024 - nature.com
Background This study evaluated the non-inferiority of dexamethasone (DEX) on day 1, with
sparing on days 2–4 in cisplatin-based chemotherapy. Methods Patients with malignant …
sparing on days 2–4 in cisplatin-based chemotherapy. Methods Patients with malignant …
Comment on “Dexamethasone-sparing on days 2–4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase …
L Celio, A Antonuzzo, MS Aapro - British Journal of Cancer, 2024 - nature.com
Minatogawa et al.[1] should be commended for conducting this important trial. Antiemetic
guidelines devised from the major international organizations recommend now olanzapine …
guidelines devised from the major international organizations recommend now olanzapine …
Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: a randomized noninferiority study
L Celio, D Cortinovis, AA Cogoni, L Cavanna… - The …, 2021 - academic.oup.com
Background To reduce the overall exposure to dexamethasone (DEX) in patients receiving
cisplatin-based chemotherapy, we evaluated the noninferiority of DEX on day 1, with or …
cisplatin-based chemotherapy, we evaluated the noninferiority of DEX on day 1, with or …
Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor …
Y Ito, T Tsuda, H Minatogawa, S Kano… - Journal of Clinical …, 2018 - ascopubs.org
Purpose We evaluated the noninferiority of dexamethasone (DEX) on day 1, with sparing on
days 2 and 3, combined with neurokinin-1 receptor antagonist (NK1-RA) and palonosetron …
days 2 and 3, combined with neurokinin-1 receptor antagonist (NK1-RA) and palonosetron …
One-day versus three-day dexamethasone with NK1RA for patients receiving carboplatin and moderate emetogenic chemotherapy: a network meta-analysis
D Watanabe, H Iihara, H Fujii, A Makiyama… - The …, 2022 - academic.oup.com
Background The dexamethasone (DEX)-sparing strategy, which limits administration of DEX
to day one, is reportedly non-inferior to conventional antiemetic regimens comprising …
to day one, is reportedly non-inferior to conventional antiemetic regimens comprising …
[HTML][HTML] Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)
L Celio, D Cortinovis, AA Cogoni, L Cavanna… - Scientific Reports, 2023 - nature.com
We demonstrated the non-inferiority of a dexamethasone (DEX)-sparing (single-dose)
regimen with NEPA, a netupitant/palonosetron fixed combination, for preventing …
regimen with NEPA, a netupitant/palonosetron fixed combination, for preventing …
[HTML][HTML] Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens …
L Celio, D Cortinovis, AA Cogoni, L Cavanna… - BMC cancer, 2022 - Springer
Background The non-inferiority of dexamethasone (DEX) on day 1, with or without low-dose
DEX on days 2 and 3, combined with oral NEPA (netupitant/palonosetron), compared with …
DEX on days 2 and 3, combined with oral NEPA (netupitant/palonosetron), compared with …
A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of …
AA Fauser, G Pizzocaro, J Schueller, D Khayat… - Supportive care in …, 2000 - Springer
Fractionated cisplatin-containing regimens are routinely used for chemotherapy in certain
types of cancer. Dolasetron has been shown to be effective in preventing acute emesis …
types of cancer. Dolasetron has been shown to be effective in preventing acute emesis …
Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer
J Rinehart, S Arnold, G Kloecker, A Lim… - Cancer chemotherapy …, 2013 - Springer
Purpose Pre-clinical and early-phase clinical studies have demonstrated that
dexamethasone (DEX) administration prior to chemotherapy reduces toxicity and enhances …
dexamethasone (DEX) administration prior to chemotherapy reduces toxicity and enhances …
Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based …
Purpose Dexamethasone (DEX)-sparing strategies (one-day DEX) with palonosetron as
doublet antiemetic prophylaxis have previously been studied. However, DEX-sparing …
doublet antiemetic prophylaxis have previously been studied. However, DEX-sparing …